Professor Saskia Middeldorp talks about two very important trails were published on LMWH use in pregnancy in 2022. The first one is the Highlow study on the optimal dosing of LMWH in pregnant and post-partum women with the history of VTE. The second one is the ALPINE trial, presented at this year’s ASH congress.

Video: https://medicaldigest.org/scientific-contents/interview:lmwh-use-pregnancy-highlow-and-alpine-trial

Professor Hope Rugo were speaker and co-author of several presentations at this years San Antonio Breast Cancer Symposium. We asked her about early stage HR+, HER2-negative breast cancer. For example, updated results of TAILORx trial on the need for adjuvant chemo and the 42 months data of the MonrachE trial.

Video: https://medicaldigest.org/scientific-contents/interview:treatment-options-early-hr-her2-breast-cancer

Professor Hope Rugo were speaker and co-author of several presentations at this years San Antonio Breast Cancer Symposium. We asked her about triple negative Breast Cancer. Where is the role of immunotherapy in early triple negative breast cancer? What is the benefit it can provide in the neoadjuvant and post-neoadjuvant setting on the basis of the current scientific evidence?

Video: https://medicaldigest.org/scientific-contents/interview:post-neoadjuvant-therapy-triple-negative-breast-cancer

Professor Virginia Kaklamani speak about the novelties and state of the art treatment presented at SABCS 2022. (DESTINY-Breast02 trial Trastuzumab Deruxtecan,  CDK4/6i elacestrant, EMERALD trial, AKT inhibitor capivasertib,POSITIVE trial)

Video: https://medicaldigest.org/scientific-contents/interview:highlights-san-antonio-breast-cancer-symposium-2022

Professor Michael Lincoff shares with us a discussion occurred during the EASD 2022 meeting, this was focusing on the modification of cardiovascular risk in patients with obesity with the GLP-1 receptor agonists.

Video: https://congressreport.eu/scientific-contents/interview:targeting-cv-risk-factors-glp-1-ras-people-obesity

Professor Tina Vilsbøll chaired a very interesting session looking into once weekly insulin.

Video: https://congressreport.eu/scientific-contents/interview:once-weekly-insulin-onwards-2-study

We asked Professor Silvio Inzucchi about the key messages of the DELIVER study, he talked about this topic at the recent EASD 2022.

Video: https://congressreport.eu/scientific-contents/interview:hfpef-hiding-your-practice-key-messages-deliver-study-dapagliflozin-heart-failure-mildly-reduced-or-preserved-ejection-fraction

Domenica Rubino, Director of Washington Center for Weight Management & Research at Arlington, Virginia, USA, held a very interesting lecture about weight control at the recent EASD 2022 Congress.

Video: https://congressreport.eu/scientific-contents/interview:semaglutide-24-mg-improved-glucose-metabolism-and-reverted-prediabetes-normoglycaemia-adults-overweight-or-obesity-vs-liraglutide-30-mg

Professor Timothy Garvey, Director of Diabetes Research Center at University of Alabama presented new data from the STEP trial program at this year EASD Congress in Stockholm.

Video: https://congressreport.eu/scientific-contents/interview:semaglutide-24-mg-reduces-10-year-type-2-diabetes-risk-people-overweight-or-obesity

Continuous glucose monitoring gives us the opportunity to better analyze diabetes. The new insights help us to improve the therapy of our patients in the active daily life and even during physical exercise. Dr. Othmar Moser held two lectures about this topic the recent EASD 2022 congress.

Video: https://congressreport.eu/scientific-contents/interview:lets-talk-about-cgm-evidence-using-basal-insulins-t1d-daily-life-and-when-exercising